Ionis Pharmaceuticals, Inc. Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Ionis Pharmaceuticals, Inc. (IONS) had Unrecognized Tax Benefits that Would Impact Effective Tax Rate of $200.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate · last filed 2026-02-26
- 2025-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $200.00K.
- 2024-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $300.00K.
- 2023-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $300.00K.
- 2022-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $6.20M.
| Period end | Unrecognized Tax Benefits that Would Impact Effective Tax Rate | Unrecognized Tax Benefits that Would Impact Effective Tax Rate as first filed |
|---|---|---|
| 2025-12-31 | $200.00K 10-K · filed 2026-02-26 | |
| 2024-12-31 | $300.00K 10-K · filed 2026-02-26 | |
| 2023-12-31 | $300.00K 10-K · filed 2026-02-26 | |
| 2022-12-31 | $6.20M 10-K · filed 2025-02-19 | |
| 2021-12-31 | $6.20M 10-K · filed 2024-02-21 | |
| 2020-12-31 | $6.40M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $400.00K 10-K · filed 2022-02-25 | $21.70M 10-K · filed 2020-03-02 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 | $55.50M 10-K · filed 2019-03-01 |
| 2017-12-31 | $63.60M 10-K · filed 2018-02-28 | |
| 2016-12-31 | $46.40M 10-K · filed 2017-03-01 | |
| 2015-12-31 | $33.30M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |